Nimodipine
Active ingredient: Nimodipine
In short: Nimodipine oral solution is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., H
What is Nimodipine used for?
Nimodipine oral solution is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I to V).
Nimodipine dosage
Administer only enterally (e.g., oral, nasogastric tube, or gastric tube route). Do not administer intravenously or by other parenteral routes. For all routes of administration, begin nimodipine oral solution within 96 hours of the onset of SAH. Administer one hour before a meal or two hours after a meal for all routes of administration
.
The recommended oral dosage is 60 mg/20 mL (3 mg/mL) every 4 hours for 21 consecutive days.
Using the oral syringe, administer 60 mg/20 mL (3 mg/mL) every 4 hours into a nasogastric or gastric tube for 21 consecutive days. For each dose, refill the syringe with 20 mL of 0.9% saline solution and then flush any remaining contents from nasogastric or gastric tube into the stomach.
In patients with cirrhosis, reduce the dosage to 10 mL (30 mg) every 4 hours
.
How to take Nimodipine — instructions & advice from the label
Inform patients that the most frequent adverse reaction associated with nimodipine is decreased blood pressure
.
Inform them that use of nimodipine oral solution with anti-hypertensives can cause increased drop in blood pressure
.
Patients should be aware that ingestion of grapefruit or grapefruit juice should be avoided when taking nimodipine oral solution due to its ability to increase nimodipine plasma concentrations and potential to increase the risk of hypotension
.
Advise patients to notify their healthcare provider if they become pregnant during treatment or plan to become pregnant during therapy
.
Advise female patients to notify their physicians if they intend to breastfeed or are breastfeeding an infant
.
For more information, call at 1-866-495-1995.
Manufactured for:
Camber Pharmaceuticals, Inc.
Piscataway, NJ 08854.
By: Annora Pharma Pvt. Ltd.
Sangareddy - 502313, Telangana, India.
Revised: 03/2024
Warnings & precautions
Do not take this medicine if: None.
Blood pressure should be carefully monitored during treatment with nimodipine. In clinical studies of patients with subarachnoid hemorrhage, about 5% of nimodipine-treated patients compared to 1% of placebo-treated patients had hypotension and about 1% of nimodipine-treated patients left the study because of this
.
Given that the plasma levels of nimodipine are increased in patients with cirrhosis, these patients are at higher risk of adverse reactions. Therefore, monitor blood pressure and pulse rate closely and administer a lower dosage
.
Concomitant use of strong inhibitors of CYP3A4, such as some macrolide antibiotics (e.g., clarithromycin, telithromycin), some HIV protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, saquinavir), some HCV protease inhibitors (e.g., boceprevir, telaprevir), some azole antimycotics (e.g., ketoconazole, itraconazole, posaconazole, voriconazole), conivaptan, delavirdine, and nefazodone with nimodipine should generally be avoided because of a risk of significant hypotension
.
Concomitant use of strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, St. John’s wort) and nimodipine should generally be avoided, as nimodipine plasma concentration and efficacy may be significantly reduced
.
Nimodipine side effects
The safety and efficacy of nimodipine oral solution in the treatment of patients with SAH is based on adequate and well-controlled studies of nimodipine oral capsules in patients with SAH. Nimodipine oral solution has comparable bioavailability to nimodipine oral capsules.
The following clinically significant adverse reaction appears in other sections of the labeling:
• Hypotension
.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
In clinical trials of nimodipine oral capsules in patients with SAH, eleven percent (92 of 823) of nimodipine-treated patients reported adverse events compared to six percent (29 of 479) of placebo-treated patients. The most common adverse event was decreased blood pressure in 4.4% of nimodipine-treated patients. The events reported with a frequency greater than 1% are displayed in Table 1 by dose. …
Drug interactions
Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. In Europe, nimodipinewas observed to occasionally intensify the effect of antihypertensive drugs taken concomitantly by hypertensive patients; this phenomenon was not observed in North American clinical trials. Blood pressure should be carefully monitored, and dose adjustment of the blood pressure lowering drug(s) may be necessary.
Nimodipine plasma concentration can be significantly increased when concomitantly administered with strong CYP3A4 inhibitors. As a consequence, the blood pressure lowering effect may be increased. Therefore, the concomitant administration of nimodipine and strong CYP3A4 inhibitors should generally be avoided
. …
About this medicine
Nimodipine oral solution contains nimodipine, a dihydropyridine calcium channel blocker. Nimodipine is isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(
m-nitrophenyl)-3,5-pyridinedicarboxylate. It has a molecular weight of 418.45 and a molecular formula of C
21H
26N
2O
7. The structural formula is:
Nimodipine USP is a light yellow or yellow, crystalline powder, freely soluble in ethyl acetate, sparingly soluble in ethanol, practically insoluble in water.
Nimodipine oral solution contains 60 mg of nimodipine per 20 mL. In addition, the oral solution contains the following inactive ingredients: dibasic sodium phosphate anhydrous, ethanol 0.63% v/v, glycerin, methylparaben, monobasic sodium phosphate monohydrate, polyethylene glycol 400 and purified water.
How it works: Nimodipine is a dihydropyridine calcium channel blocker. The contractile processes of smooth muscle cells are dependent upon calcium ions, which enter these cells during depolarization as slow ionic transmembrane currents. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f829de8b-fabd-4aec-ac8d-c9aaef7be55b. Read the full official label on DailyMed.